MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apimeds Pharmaceuticals US, Inc. Common Stock (NY:APUS)

0.8580 -0.0320 (-3.60%)
Official Closing Price Updated: 8:00 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 310,510
Open 0.9000
Bid (Size) 0.9200 (100)
Ask (Size) 1.070 (100)
Prev. Close 0.8900
Today's Range 0.7903 - 1.000
52wk Range 0.7903 - 40.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MissionIRNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Offers Secure Gateway to Digital Assets
Via Investor Brand Network
MindWave Innovations Inc. (NYSE American: APUS) Is Building an Ecosystem Designed to Unlock the Full Potential of Digital Asset Treasury Management
Via Investor Brand Network
Topics Artificial Intelligence Economy

Performance

YTD
-94.8%
-94.8%
1 Month
-39.6%
-39.6%
3 Month
-47.4%
-47.4%
6 Month
-95.2%
-95.2%
1 Year
-95.1%
-95.1%

More News

Read More
TechMediaBreaks – MindWave Innovations Inc. (NYSE American: APUS) Taps Growing Demand for Yield-Generating Solutions
Via Investor Brand Network
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
MindWave Innovations Inc. (NYSE American: APUS) Builds Institutional Bridge for Bitcoin Treasury Adoption
Via Investor Brand Network
Topics Economy
Bitcoin as a Corporate Treasury Asset: How MindWave Innovations Inc. (NYSE American: APUS) Is Redefining Institutional Yield Infrastructure
Via Investor Brand Network
Topics Artificial Intelligence Economy
The Infrastructure Gap Behind Corporate Bitcoin Adoption
Via Investor Brand Network
News headline image
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
From The Rosen Law Firm, P.A.
Via Business Wire
MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
Via CryptoCurrencyWire
Topics Artificial Intelligence Economy
MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
Via Investor Brand Network
Topics Artificial Intelligence Economy
News headline image
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
From Apimeds Pharmaceuticals US, Inc.
Via GlobeNewswire
News headline image
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
From Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire

Frequently Asked Questions

Is Apimeds Pharmaceuticals US, Inc. Common Stock publicly traded?
Yes, Apimeds Pharmaceuticals US, Inc. Common Stock is publicly traded.
What exchange does Apimeds Pharmaceuticals US, Inc. Common Stock trade on?
Apimeds Pharmaceuticals US, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Apimeds Pharmaceuticals US, Inc. Common Stock?
The ticker symbol for Apimeds Pharmaceuticals US, Inc. Common Stock is APUS on the New York Stock Exchange
What is the current price of Apimeds Pharmaceuticals US, Inc. Common Stock?
The current price of Apimeds Pharmaceuticals US, Inc. Common Stock is 0.8580
When was Apimeds Pharmaceuticals US, Inc. Common Stock last traded?
The last trade of Apimeds Pharmaceuticals US, Inc. Common Stock was at 06/25/26 08:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story